Corbus Pharmaceuticals

Corbus Pharmaceuticals, based in Norwood, MA, the United States, is a biotechnology company. Corbus Pharmaceuticals is a pharmaceutical company developing cancer treatments, including a Nectin-4-targeted therapy, alongside an obesity programme. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing CRB-601 monoclonal antibody and CRB-701. The largest, NCT06265727 (A Phase 1/2 Study to Investigate CRB-701 in Solid Tumours), plans to enrol 348 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.